Your web browser is out of date. For the best experience on Zimmer websites please upgrade to the latest version of Internet Explorer, Chrome, or Firefox.

Zimmer, Inc.

FDA 522 Zimmer Metal-on-Metal Hip Explant Study


The Food and Drug Administration (FDA), pursuant to Section 522 of the Food, Drug and Cosmetic Act, 21 USC § 3601, has ordered medical device manufacturers, including Zimmer, Inc. (“Zimmer”), to conduct post market surveillance studies of their metal-on-metal hip implants.

Part of the post-market surveillance includes the study of explanted retrievals when made available after medically necessary surgical intervention. Below you will find copies of all the pertinent letters and forms for this activity.